Sydney, Australia 23 August 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined their scientific advisory board. Dr O’Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles.…
Sydney, Australia 10 July 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at Royal North Shore Hospital in Sydney has been completed and recruitment has commenced for its SARTATE™ clinical trial. Clarity’s SARTATE™ trial is a Peptide Receptor Radionuclide Therapy clinical trial…
Sydney, Australia 6 June 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Michelle Parker as Head of Clinical Operations at Clarity. Michelle has enjoyed a diverse career spanning across Nuclear Medicine/PET and pharmaceutical industries, both locally and abroad over the last 20…
Sydney, Australia 20 April 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it was invited to give oral presentations and presentations of their posters at the upcoming 12th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) in Melbourne. Clarity’s CEO, Dr…
Sydney, Australia 21 February 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Andreas Kjaer has joined their scientific advisory board. Andreas Kjaer is a professor at the University of Copenhagen and is chief physician and head of research at the Department of…
Sydney, Australia 13 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by the St Vincent Hospital (Melbourne) Human Research Ethics Committee for the Company’s clinical trial of SARTATE™ for meningioma. Clarity filed its ethics submission for the…
Sydney, Australia 6 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully in-licensed a patent application on a Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and treating prostate cancer from the University of Melbourne. Clarity is also pleased to…
Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial. Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET)…
Sydney, Australia 31 October 2017 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Richard Wahl has joined their scientific advisory group. Richard Wahl, M.D., is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology…
Sydney, Australia 15 August 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by The Children’s Hospital at Westmead for its SARTATE™ Kids clinical trial for neuroblastoma. Clarity filed its ethics submission to the Sydney Children’s Hospital Network Human…